Scot Mente

Covalent Associates (United States) — United States

Medicine · Health Sciences

20h-index1.3kcitations64works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(24), Chronic Myeloid Leukemia Treatments(21), Click Chemistry and Applications(18), Computational Drug Discovery Methods(9), Cytokine Signaling Pathways and Interactions(8)

Publications64 total

Molecular Communication in Bounded Spherical Region With Anomalous Diffusion Phenomenon
IEEE Transactions on Molecular Biological and Multi-Scale Communications·2025
Supplementary Figures S1-S16 from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2025Open Access
Supplementary Table S2 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Figure S6 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Table S5 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Figure S10 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Figure S8 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Figure S2 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Figure S1 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Figure S5 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Table S3 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Table S6 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Figure S9 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Figure S12 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Table S4 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Figure S3 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Figure S7 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Figure S11 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Table S7 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
Supplementary Table S1 from Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations
2025Open Access
page 1 of 4Next →

Frequent Co-authors

Anupong Tangpeerachaikul(18), Henry E. Pelish(18), Joshua C. Horan(17), Joe Magrino(12), Franklin Gu(12), Travis T. Wager(7), Jayvardhan Pandit(5), Alexander Drilon(5), Benjamin Besse(5), D. Ross Camidge(5), Linh Nguyen-Phuong(5), Satoshi Yoda(5), Yuting Sun(5), Nancy E. Kohl(5), James R. Porter(5), Matthew D. Shair(5), Viola W. Zhu(5), Aaron N. Hata(5), W. Marston Linehan(5), Shenping Liu(4)